159 related articles for article (PubMed ID: 37345469)
1. CAR T-cell therapy for central nervous system lymphomas: blood and cerebrospinal fluid biology, and outcomes.
Lacan C; Caron J; Tarantino N; Fouquet B; Cherai M; Parizot C; Morel V; Souchet L; Uzunov M; Gorochov G; Nguyen-Quoc S; Sourdeau E; Vieillard V; Miyara M; Vinit A; Solorzano S; Soussain C; Houillier C; Metz C; Autran B; Litvinova E; Le Garff-Tavernier M; Norol F; Roos-Weil D; Choquet S; Guihot A; Baron M
Haematologica; 2023 Dec; 108(12):3485-3490. PubMed ID: 37345469
[No Abstract] [Full Text] [Related]
2. Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Children With Central Nervous System Leukemia.
Zhang L; Zuo Y; Lu A; Wu J; Jia Y; Wang Y; Zhang L
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e410-e414. PubMed ID: 33526401
[TBL] [Abstract][Full Text] [Related]
3. Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients.
Cook MR; Dorris CS; Makambi KH; Luo Y; Munshi PN; Donato M; Rowley S; Saad A; Goy A; Dunleavy K; Ali A
Blood Adv; 2023 Jan; 7(1):32-39. PubMed ID: 36260735
[TBL] [Abstract][Full Text] [Related]
4. The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma.
Wang X; Huynh C; Urak R; Weng L; Walter M; Lim L; Vyas V; Chang WC; Aguilar B; Brito A; Sarkissian A; Bandara NA; Yang L; Wang J; Wu X; Zhang J; Priceman SJ; Qin H; Kwak LW; Budde LE; Thomas SH; Clark MC; Popplewell L; Siddiqi T; Brown CE; Forman SJ
Cancer Immunol Res; 2021 Jan; 9(1):75-88. PubMed ID: 33093217
[TBL] [Abstract][Full Text] [Related]
5. Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review of Literature.
Asghar N; Masood A; Dhaliwal A; Khurana S; Davis J; Hashmi H; Husnain M
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):15-21. PubMed ID: 36328891
[TBL] [Abstract][Full Text] [Related]
6. CAR T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network.
Alcantara M; Houillier C; Blonski M; Rubio MT; Willems L; Rascalou AW; Le Garff-Tavernier M; Maloum K; Bravetti C; Souchet L; Roos-Weil D; Morel V; Uzunov M; Metz C; Dhib-Charfi M; Nguyen S; Shor N; Psimaras D; Weiss N; Jacque N; Solorzano S; Gauthier N; Le Cann M; Norol F; Soussain C; Choquet S
Blood; 2022 Feb; 139(5):792-796. PubMed ID: 34871363
[No Abstract] [Full Text] [Related]
7. Chimeric antigen receptor T-cell therapy following autologous transplantation for secondary central nervous system lymphoma: A case report.
Yagi Y; Kanemasa Y; Ohigashi A; Morita Y; Tamura T; Nakamura S; Otsuka Y; Kishida Y; Kageyama A; Shimizuguchi T; Toya T; Shimizu H; Najima Y; Kobayashi T; Haraguchi K; Doki N; Okuyama Y; Omuro Y; Shimoyama T
Medicine (Baltimore); 2021 Nov; 100(44):e27733. PubMed ID: 34871273
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid interleukin-10 may be a useful biomarker for atypical primary central nervous system lymphoma relapse.
Autier L; Le Garff-Tavernier M; Mathon B; Martin-Duverneuil N; Hoang-Xuan K; Houillier C
Rev Neurol (Paris); 2021 Apr; 177(4):436-439. PubMed ID: 33190919
[No Abstract] [Full Text] [Related]
9. Primary Central Nervous System Lymphomas.
Chukwueke U; Grommes C; Nayak L
Hematol Oncol Clin North Am; 2022 Feb; 36(1):147-159. PubMed ID: 34801161
[TBL] [Abstract][Full Text] [Related]
10. Primary Central Nervous System Lymphoma: Evolving Biologic Insights and Recent Therapeutic Advances.
Chihara D; Dunleavy K
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):73-79. PubMed ID: 33288483
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products.
Hunter BD; Rogalski M; Jacobson CA
Expert Opin Biol Ther; 2019 Nov; 19(11):1157-1164. PubMed ID: 31342797
[No Abstract] [Full Text] [Related]
12. [CAR-T cells in lymphomas: Current and evolving role].
Messéant O; Houot R
Bull Cancer; 2021 Oct; 108(10S):S28-S39. PubMed ID: 34920805
[TBL] [Abstract][Full Text] [Related]
13. Flare-up phenomenon or pseudoprogression after CAR T-cell infusion in non-Hodgkin aggressive lymphomas.
Sortais C; Cordeil S; Bourbon E; Idlhaj M; Ferrant E; Safar V; Golfier C; Lazareth A; Bouafia-Sauvy F; Tordo J; Ghesquières H; Sesques P; Bachy E
Leuk Lymphoma; 2023 Mar; 64(3):707-711. PubMed ID: 36573418
[No Abstract] [Full Text] [Related]
14. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
Pehlivan KC; Duncan BB; Lee DW
Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Axicabtagene Ciloleucel and Tisagenlecleucel Administration in Lymphoma Patients With Secondary CNS Involvement: A Systematic Review.
Wu X; Zhang X; Xun R; Liu M; Sun Z; Huang J
Front Immunol; 2021; 12():693200. PubMed ID: 34290712
[TBL] [Abstract][Full Text] [Related]
16. CD19 or CD20 CAR T Cell Therapy Demonstrates Durable Antitumor Efficacy in Patients with Central Nervous System Lymphoma.
Liu R; Cheng Q; Kang L; Wang E; Li Y; Zhang J; Xiao H; Zhang Y; Chu L; Chen X; Zhang C; Tan J; Xu N; Li M; Yu L; Li X
Hum Gene Ther; 2022 Mar; 33(5-6):318-329. PubMed ID: 35152726
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological analysis and specific discriminating markers of interleukin detection in cerebrospinal fluid with primary central nervous system lymphoma: results from a retrospective study.
Li J; Tang X; Luo X; Liu L; Li D; Yang L
Ann Hematol; 2023 Aug; 102(8):2153-2163. PubMed ID: 37289220
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and treatment of central nervous system involvement in non-Hodgkin's lymphoma.
Bierman P; Giglio P
Hematol Oncol Clin North Am; 2005 Aug; 19(4):597-609, v. PubMed ID: 16083825
[TBL] [Abstract][Full Text] [Related]
19. Recent Advances in CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
Kallam A; Vose JM
Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):751-757. PubMed ID: 31648957
[TBL] [Abstract][Full Text] [Related]
20. Recapitulated Late-Onset Inflammatory Toxicities and Progressive Dysautonomia with Persistence of Central Memory CD4+ Chimeric Antigen Receptor T Cells in a Case of Transformed Follicular Lymphoma: Case Report.
Nishimoto M; Takakuwa T; Kuno M; Makuuchi Y; Okamura H; Nakashima Y; Koh H; Namba H; Itoh Y; Hino M; Nakamae H
Acta Haematol; 2023; 146(4):338-342. PubMed ID: 37088083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
